Mankind Pharma has reported its financial results for the third quarter of the fiscal year ending December 31, 2024. The company experienced a 16.2% decline in net profit, totaling ₹380.2 crore, compared to ₹453.8 crore in the same quarter last year. However, Mankind Pharma saw a revenue increase of 24%, reaching ₹3,230 crore, up from ₹2,607 crore year-over-year. The company's EBITDA rose by 36.8% to ₹830 crore, with a margin improvement to 25.7%, compared to 23.3% in the previous year. This mixed performance has been attributed to a sharp rise in expenses, which impacted profit expectations.